Matthew C. Hill

Matthew C. Hill (finance chief) discloses dealings in 2 companies, chiefly Apyx Medical Corp and PDS Biotechnology Corp. Over a trading history stretching from 13 December 2021 to 13 August 2024, the count stands at 4 filings.

Every open-market trade on record is a purchase: 4 purchases worth €37k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2025 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €5,824. Of 4 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 3 March 2025 with an open-market purchase (€6,165) in Apyx Medical Corp. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.